![]() |
Volumn 26, Issue 8, 2017, Pages 728-730
|
JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus
|
Author keywords
chilblain lupus erythematosus; CXCL10; interferon; JAK STAT pathway; kinase inhibitor
|
Indexed keywords
CXCL9 CHEMOKINE;
GAMMA INTERFERON INDUCIBLE PROTEIN 10;
MUCIN;
MYXOVIRUS RESISTANCE PROTEIN A;
RUXOLITINIB;
CYTOKINE;
JANUS KINASE INHIBITOR;
PYRAZOLE DERIVATIVE;
AGED;
CASE REPORT;
CHILBLAIN;
DERMATITIS;
DRUG EFFECT;
DRUG MECHANISM;
FEMALE;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
IN VITRO STUDY;
KERATINOCYTE;
LETTER;
MYELOFIBROSIS;
PROTEIN EXPRESSION;
SIDE EFFECT;
SKIN DEFECT;
SKIN LUPUS ERYTHEMATOSUS;
CASE CONTROL STUDY;
CELL CULTURE;
METABOLISM;
AGED;
CASE-CONTROL STUDIES;
CELLS, CULTURED;
CYTOKINES;
FEMALE;
HUMANS;
JANUS KINASE INHIBITORS;
KERATINOCYTES;
LUPUS ERYTHEMATOSUS, CUTANEOUS;
PYRAZOLES;
|
EID: 85018743598
PISSN: 09066705
EISSN: 16000625
Source Type: Journal
DOI: 10.1111/exd.13253 Document Type: Letter |
Times cited : (43)
|
References (9)
|